{"gene":"LIMK2","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1995,"finding":"LIMK2 is a serine/threonine kinase containing two N-terminal LIM motifs and a C-terminal kinase domain; it phosphorylates serine and threonine residues of myelin basic protein in vitro, demonstrating its catalytic activity.","method":"In vitro kinase assay, immunoprecipitation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay demonstrated catalytic activity, single lab, single method","pmids":["7651734"],"is_preprint":false},{"year":1996,"finding":"LIMK2a (two LIM domains + PDZ + kinase) localizes to both cytoplasm and nucleus, while LIMK2b (one and half LIM domains) localizes mainly to cytoplasm; a truncated LIMK2-Kinase construct localizes to the nucleus. LIMK2a and LIMK2b associate with 63-kDa and 58-kDa partner proteins, respectively.","method":"Transfection studies, subcellular fractionation, immunofluorescence, co-precipitation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — direct localization experiment with co-precipitation, single lab, single study","pmids":["8954941"],"is_preprint":false},{"year":1997,"finding":"Recombinant LIMK2 exhibits autophosphorylation and serine/threonine kinase activity toward exogenous substrate MBP; endogenous LIMK2 co-precipitates with a 140 kDa tyrosine-phosphorylated protein but is not itself tyrosine phosphorylated; LIMK2 localizes in both the nucleus and a Triton X-100 soluble cytoplasmic fraction.","method":"In vitro kinase assay, stable transfection, co-precipitation, subcellular fractionation","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — in vitro kinase assay with co-precipitation, single lab","pmids":["9089416"],"is_preprint":false},{"year":2005,"finding":"PKC-delta phosphorylates LIMK2 at Ser-283 in vitro and in endothelial cells; phosphorylation at Ser-283 (but not Thr-494) inhibits nuclear import of LIMK2, retaining it in the cytoplasm. This cytoplasmic retention is associated with relief of LIMK2-mediated suppression of cyclin D1 expression and promotion of G1-to-S phase transition.","method":"EGFP-LIMK2 live imaging, FRAP, leptomycin B treatment, site-directed mutagenesis, in vitro kinase assay, immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus live-cell FRAP imaging, multiple orthogonal methods in single study","pmids":["15923181"],"is_preprint":false},{"year":2005,"finding":"Loss of neurofibromin activates a Rho-ROCK-LIMK2 pathway that elevates cofilin phosphorylation, promoting actin stress fiber formation and enhanced cell motility; this pathway requires Ras activation but is independent of Raf, PI3K, and RalGEF downstream pathways.","method":"siRNA knockdown, Western blot for phospho-cofilin, genetic epistasis with NF1-GRD re-expression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via siRNA + rescue experiment, single lab, multiple pathway controls","pmids":["16169856"],"is_preprint":false},{"year":2006,"finding":"LIMK2 activity toward cofilin does not change during normal cell division but is markedly increased when cells are arrested at mitosis by nocodazole-induced microtubule disruption, accompanied by LIMK2 hyperphosphorylation. LIMK2 localizes to the mitotic spindle during prometaphase through anaphase and to the spindle midzone during anaphase–telophase, distinct from LIMK1.","method":"Cell synchronization, in vitro kinase assay, immunofluorescence microscopy","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct kinase activity assay combined with immunofluorescence localization, single lab","pmids":["16455074"],"is_preprint":false},{"year":2008,"finding":"ROCK1 preferentially phosphorylates LIMK2 over LIMK1; direct ROCK1–LIMK2 interaction detected by FRET occurs in polarized (spread) but not blebbing cancer cells, indicating the ROCK1:LIMK2 pathway is specific to mesenchymal-mode rather than amoeboid-mode migration.","method":"FRET live-cell imaging, substrate phosphorylation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — novel FRET data for direct interaction, single lab","pmids":["18852895"],"is_preprint":false},{"year":2010,"finding":"RhoC and LIMK2 are direct transcriptional targets of p53 induced by genotoxic agents; LIMK2 activation downstream of p53 promotes cell survival following DNA damage, and LIMK inhibition sensitizes cells to radio- and chemotherapy.","method":"siRNA knockdown, pharmacological inhibition, ChIP/reporter assays (p53 target gene identification), cell viability assays","journal":"Cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA + pharmacological inhibition + direct p53 target validation, single lab, multiple methods","pmids":["21079653"],"is_preprint":false},{"year":2012,"finding":"Aurora A kinase directly phosphorylates LIMK2 at S283, T494, and T505, regulating LIMK2 kinase activity, subcellular localization, and protein levels. LIMK2 in turn positively regulates Aurora A levels, forming a positive-feedback loop. LIMK2 ablation fully abrogates Aurora-A-mediated tumorigenesis in vivo.","method":"Chemical genetic approach (analog-sensitive Aurora A), in vitro kinase assay, site-directed mutagenesis, xenograft mouse model, Western blot","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chemical genetic substrate identification plus in vitro kinase assay plus mutagenesis plus in vivo rescue, multiple orthogonal methods","pmids":["22492986"],"is_preprint":false},{"year":2012,"finding":"LIMK2 acts downstream of RhoA-ROCK to regulate astral microtubule organization through TPPP (tubulin polymerization promoting protein), independently of cofilin, during mitosis; this pathway controls spindle orientation in mitotic cells.","method":"RNAi knockdown, epistasis analysis, immunofluorescence for microtubules and spindle orientation","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi epistasis with multiple proteins, single lab, immunofluorescence readout","pmids":["22328514"],"is_preprint":false},{"year":2012,"finding":"Nf1 RasGAP SecPH domain physically interacts with LIMK2 (but not LIMK1), partially inhibiting LIMK2 kinase activity toward cofilin by preventing ROCK-mediated activation of LIMK2, thereby connecting Ras and Rho/ROCK/LIMK2/cofilin signaling.","method":"Yeast two-hybrid screening, co-immunoprecipitation, in vitro kinase assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP plus in vitro kinase inhibition assay, single lab, two orthogonal methods","pmids":["23082153"],"is_preprint":false},{"year":2012,"finding":"In LIMK2 knockout mice, keratinocytes fail to nucleate filamentous actin and remain immobile during eyelid development, resulting in eyes open at birth phenotype; this is associated with markedly reduced phospho-cofilin levels, demonstrating that LIMK2 activity and cofilin phosphorylation are required for keratinocyte migration in vivo.","method":"Knockout mouse model, immunofluorescence for F-actin and phospho-cofilin, phenotypic analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO with defined in vivo cellular phenotype and molecular readout (p-cofilin), single lab","pmids":["23071748"],"is_preprint":false},{"year":2013,"finding":"LIMK2 depletion sensitizes neuroblastoma cells to microtubule-targeted drugs by enhancing cell cycle arrest and apoptosis; LIMK2 modulates microtubule acetylation and levels of TPPP1, suggesting a role in regulating the microtubule network independent of actin/cofilin.","method":"siRNA knockdown, drug sensitivity assays, cell cycle analysis, Western blot for microtubule acetylation and TPPP1","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA with multiple functional readouts, single lab","pmids":["23991158"],"is_preprint":false},{"year":2013,"finding":"Limk2 mediates Sema3A (but not Sema3F) chemorepulsive signaling in cortical interneurons migrating through the subpallium; Limk2-siRNA-transfected interneurons fail to respond to Sema3A and aberrantly invade the developing striatum.","method":"siRNA knockdown, chemotactic assay, brain slice preparations, in utero electroporation","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA in multiple experimental systems (chemotaxis + brain slice + in utero electroporation), single lab","pmids":["23519094"],"is_preprint":false},{"year":2013,"finding":"Limk2 deletion in mice increases colon tumor size in a colitis-associated colorectal cancer model and increases gastrointestinal stem cell proliferation, demonstrating a conserved role for LIMK2 in constraining stem cell proliferation.","method":"Limk2 knockout mouse model, colitis-associated CRC model, immunostaining for LIMK2 expression and substrate phosphorylation","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined in vivo phenotype, cross-validated with Drosophila genetic analysis, single lab","pmids":["23585469"],"is_preprint":false},{"year":2017,"finding":"BMPR2 activates LIMK2 through the RhoA/ROCK pathway and also interacts directly with LIMK2; activated LIMK2 promotes phosphorylation of downstream signaling components driving osteosarcoma invasion and metastasis.","method":"iTRAQ-based phosphoproteomics, Western blot, co-immunoprecipitation, in vitro and in vivo invasion/metastasis assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics plus co-IP plus functional validation, single lab","pmids":["28938584"],"is_preprint":false},{"year":2018,"finding":"The LIMK2-1 isoform contains a C-terminal PP1 inhibitory domain absent in LIMK2a and LIMK2b. LIMK2-1 does not phosphorylate cofilin directly despite having kinase activity; instead it interacts with PP1 and partially inhibits PP1 activity toward cofilin, thereby indirectly maintaining phospho-cofilin levels and promoting actin stress fiber formation.","method":"Biochemical characterization, in vitro kinase assay, co-immunoprecipitation with PP1, PP1 activity assay, actin stress fiber imaging","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus PP1 activity assay plus co-IP plus mutagenesis analysis, multiple orthogonal methods, single lab","pmids":["30373762"],"is_preprint":false},{"year":2019,"finding":"LIMK2 directly phosphorylates TWIST1, stabilizing it by preventing its degradation; TWIST1 in turn stabilizes LIMK2 by inhibiting its ubiquitylation. Phosphorylation-dead TWIST1 acts as dominant negative and fully prevents EMT and tumor formation in vivo, establishing the LIMK2-TWIST1 signaling axis in CRPC.","method":"Chemical genetic substrate identification, in vitro kinase assay, site-directed mutagenesis, xenograft mouse model, ubiquitylation assay","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct phosphorylation validated with mutagenesis and in vivo dominant-negative rescue, multiple orthogonal methods","pmids":["30716360"],"is_preprint":false},{"year":2020,"finding":"LIMK2 phosphorylates PTEN at five sites, degrading it and inhibiting its activity, thereby activating PI3K/AKT oncogenic signaling. PTEN also degrades LIMK2 in a feedback loop (confirmed in PTEN-/- vs PTEN+/+ mouse prostates), identifying LIMK2 as the missing link between hypoxia and PTEN degradation in CRPC.","method":"In vitro kinase assay, site-directed mutagenesis, ubiquitylation assay, PTEN knockout mouse validation, xenograft model","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct phosphorylation with mutagenesis plus in vivo mouse genetic validation plus in vitro biochemistry, multiple orthogonal methods","pmids":["32931887"],"is_preprint":false},{"year":2020,"finding":"LIMK2 degrades SPOP by direct phosphorylation at three sites; SPOP promotes LIMK2 ubiquitylation in a feedback loop. LIMK2-mediated SPOP degradation stabilizes AR, ARv7, and c-Myc. Phospho-resistant SPOP completely suppresses tumorigenesis in vivo.","method":"In vitro kinase assay, site-directed mutagenesis (phospho-resistant SPOP), ubiquitylation assay, xenograft mouse model","journal":"British journal of cancer","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct phosphorylation with phospho-resistant mutagenesis rescue in vivo, multiple orthogonal methods, single lab","pmids":["33311589"],"is_preprint":false},{"year":2020,"finding":"LIMK2 inhibition blocks SRPK1 phosphorylation and its kinase activity; SRPK1 identified as a LIMK2 substrate by SILAC-based phosphoproteomics. Genetic or pharmacological inhibition of LIMK2 or SRPK1 equivalently blocks metastatic attributes of TNBC cells.","method":"SILAC-based phosphoproteomics, shRNA knockdown, pharmacological inhibition, in vivo metastasis mouse model","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics substrate identification with functional validation, single lab","pmids":["32859889"],"is_preprint":false},{"year":2021,"finding":"LIMK2 directly phosphorylates NKX3.1, promoting its degradation in CRPC cells. NKX3.1 in turn promotes LIMK2 ubiquitylation. LIMK2 also downregulates NKX3.1 mRNA. LIMK2-NKX3.1 crosstalk regulates AR, ARv7, and AKT signaling.","method":"In vitro kinase assay, co-immunoprecipitation, ubiquitylation assay, Western blot, xenograft mouse model","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation assay plus ubiquitylation assay plus in vivo validation, single lab","pmids":["34066036"],"is_preprint":false},{"year":2021,"finding":"LIMK2 phosphorylates cofilin to regulate F-actin dynamics in airway smooth muscle (ASM); LIMK2-deficient ASM shows ~30% inhibition of contractile force and reduced F/G-actin ratio. LIMK2 functions independently of cross-bridge movement and is required for 5-HT-evoked length-sensitive contraction but not acetylcholine-evoked contraction.","method":"LIMK2 knockout mouse, force measurements, F/G-actin ratio assay, phospho-cofilin Western blot","journal":"Journal of genetics and genomics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with defined contractile phenotype and molecular readout, multiple functional assays","pmids":["34353741"],"is_preprint":false},{"year":2023,"finding":"LIMK2 phosphorylates G3BP1, and G3BP1 is required for ESM1 mRNA stability. LIMK2→G3BP1→ESM1 pathway promotes melanoma tumor growth and metastasis; G3BP1 knockdown mirrors LIMK2 inhibition and ESM1 ectopic expression rescues LIMK2 or G3BP1 inhibition.","method":"Phosphoproteomics, shRNA knockdown, RNA-seq, rescue experiments, in vivo mouse tumor models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics substrate identification with epistasis rescue, single lab","pmids":["36922679"],"is_preprint":false},{"year":2025,"finding":"LIMK2 phosphorylates MST4 at T178, activating its kinase function; activated MST4 then phosphorylates NPM1 at T95, which is essential for centrosome clustering and tumor cell proliferation. LIMK2 knockout attenuates esophageal tumorigenesis in vivo; pharmacological LIMK2 inhibition disrupts centrosome clustering causing multipolar spindle assembly and apoptosis.","method":"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, shRNA knockdown, xenograft and 4NQO mouse tumor models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct phosphorylation with mutagenesis validated by in vivo mouse models and pharmacological inhibition, multiple orthogonal methods","pmids":["40775397"],"is_preprint":false},{"year":2025,"finding":"The LIMK2-1 isoform is phosphorylated predominantly by protein kinase C and, when phosphorylated, inhibits PP1 catalytic subunit (PP1c) isoforms and the myosin phosphatase (MP) holoenzyme with IC50 ~28–47 nM, functioning as a CPI-17-like phosphatase inhibitor. LIMK2-1 interacts with PP1c isoforms.","method":"Flag-LIMK2-1 overexpression, co-immunoprecipitation with PP1c, in vitro phosphatase activity assay, calyculin A treatment, phosphospecific antibody","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphatase assay with IC50 determination plus co-IP plus site-specific phosphorylation analysis, multiple orthogonal methods","pmids":["40806479"],"is_preprint":false},{"year":2019,"finding":"LIMK2a knockout mice show prolonged bleeding after injury; LIMK2 protein is expressed in human and mouse platelets and LIMK2a-deficient mice exhibit impaired platelet spreading, aggregation, and thrombus formation, demonstrating a role for LIMK2 in platelet cytoskeletal function.","method":"LIMK2a knockout mouse, platelet spreading assay, aggregation assay, thrombus formation, Western blot","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO mouse with multiple platelet functional readouts, single lab","pmids":["31926945"],"is_preprint":false},{"year":2021,"finding":"LIMK2 depletion in human embryonic stem cells inhibits definitive endoderm generation and promotes neuroectodermal fate; knockdown reduces actin stress fiber assembly and cofilin phosphorylation, and impairs EMT-gene upregulation and cell migration during endodermal differentiation.","method":"siRNA knockdown, immunofluorescence for F-actin, Western blot for p-cofilin, RT-PCR for lineage markers","journal":"In vitro cellular & developmental biology. Animal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — siRNA with multiple readouts in hESC system, single lab","pmids":["33977398"],"is_preprint":false},{"year":2022,"finding":"TP receptor activation signals through Gα13-RhoA/C-ROCK-LIMK2 to inhibit angiogenic sprouting of human endothelial cells; pharmacological ROCK or LIMK2 inhibition reverses TP-agonist-induced endothelial cell tension and focal adhesion dysregulation.","method":"RNAi gene silencing, pharmacological inhibition, HUVEC spheroid sprouting assay, FRET biosensors for RhoA/C activity, live-cell imaging","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi plus pharmacological inhibition plus FRET biosensors for upstream activators, single lab","pmids":["35525325"],"is_preprint":false}],"current_model":"LIMK2 is a serine/threonine kinase that acts downstream of Rho GTPases (RhoA/C, RhoC) via ROCK1/2 and PAK to phosphorylate and inactivate cofilin, thereby stabilizing actin filaments and regulating cytoskeletal dynamics required for cell migration, mitosis, and mechanotransduction; its activity and nuclear-cytoplasmic shuttling are regulated by upstream phosphorylation events (PKC-delta at Ser-283, Aurora A at S283/T494/T505, ROCK at activating sites), and beyond cofilin it directly phosphorylates substrates including TWIST1, PTEN, SPOP, NKX3.1, MST4, and SRPK1 to promote context-dependent oncogenic or survival signaling; the LIMK2-1 isoform uniquely inhibits PP1 phosphatase in a PKC-phosphorylation-dependent manner rather than directly phosphorylating cofilin."},"narrative":{"mechanistic_narrative":"LIMK2 is a serine/threonine kinase, defined by N-terminal LIM motifs, a PDZ domain, and a C-terminal kinase domain, that integrates Rho-family GTPase signaling with actin cytoskeletal dynamics and cell cycle control [PMID:7651734, PMID:8954941]. Its canonical output is phosphorylation and inactivation of cofilin downstream of a RhoA/RhoC–ROCK module, stabilizing F-actin to drive cell migration and contractility; this axis is required in vivo for keratinocyte migration during eyelid closure, airway smooth muscle contraction, platelet spreading and thrombus formation, and endothelial responses [PMID:23071748, PMID:34353741, PMID:31926945, PMID:35525325]. ROCK1 preferentially activates LIMK2 over LIMK1 in a manner specific to mesenchymal-mode migration, and the pathway is constrained by neurofibromin, whose loss elevates cofilin phosphorylation and motility [PMID:18852895, PMID:16455074, PMID:23082153]. LIMK2 activity and nuclear–cytoplasmic shuttling are tuned by upstream phosphorylation: PKC-delta phosphorylates Ser-283 to block nuclear import and relieve suppression of cyclin D1, while Aurora A phosphorylates S283/T494/T505 in a reciprocal positive-feedback loop essential for Aurora-A-driven tumorigenesis [PMID:15923181, PMID:22492986]. During mitosis LIMK2 localizes to the spindle and, downstream of RhoA-ROCK, regulates astral microtubule organization and spindle orientation through TPPP independently of cofilin, and supports centrosome clustering via an MST4–NPM1 cascade [PMID:16455074, PMID:22328514, PMID:40775397]. As a p53 target, LIMK2 promotes survival after DNA damage [PMID:21079653]. Beyond cofilin, LIMK2 directly phosphorylates a set of substrates—TWIST1, PTEN, SPOP, NKX3.1, SRPK1, G3BP1, and MST4—frequently within mutual stabilization/degradation feedback loops, to drive context-dependent oncogenic and EMT signaling in prostate, breast, melanoma, and esophageal cancers [PMID:30716360, PMID:32931887, PMID:33311589, PMID:32859889, PMID:34066036, PMID:36922679, PMID:40775397]. A distinct isoform, LIMK2-1, lacks direct cofilin kinase output and instead, when phosphorylated by PKC, acts as a CPI-17-like inhibitor of PP1 and myosin phosphatase to indirectly maintain phospho-cofilin [PMID:30373762, PMID:40806479].","teleology":[{"year":1995,"claim":"Established that LIMK2 is a bona fide serine/threonine kinase, defining its catalytic identity and domain architecture.","evidence":"In vitro kinase assay on MBP from immunoprecipitated LIMK2 with two LIM motifs and a kinase domain","pmids":["7651734"],"confidence":"Medium","gaps":["No physiological substrate identified","Regulation of catalytic activity unknown"]},{"year":1996,"claim":"Resolved that LIMK2 isoforms differ in domain content and partition between nucleus and cytoplasm, raising the question of compartment-specific functions.","evidence":"Transfection, subcellular fractionation, immunofluorescence, and co-precipitation of isoforms LIMK2a/LIMK2b","pmids":["8954941"],"confidence":"Medium","gaps":["Identity of 63/58-kDa partner proteins unknown","Functional consequence of differential localization not tested"]},{"year":2005,"claim":"Defined PKC-delta phosphorylation of Ser-283 as a switch controlling LIMK2 nuclear import and cell cycle progression, linking post-translational control to function.","evidence":"FRAP live imaging, leptomycin B, site-directed mutagenesis, and in vitro kinase assay in endothelial cells","pmids":["15923181"],"confidence":"High","gaps":["Nuclear substrate(s) of LIMK2 not identified","Direct mechanism linking shuttling to cyclin D1 unresolved"]},{"year":2005,"claim":"Placed LIMK2 in a Ras-Rho-ROCK pathway constrained by neurofibromin, showing its cofilin-phosphorylating activity drives stress fiber formation and motility.","evidence":"siRNA knockdown, phospho-cofilin Western blot, and NF1-GRD rescue epistasis","pmids":["16169856"],"confidence":"Medium","gaps":["Direct vs indirect NF1 effect not distinguished here","Contribution relative to ROCK-cofilin baseline not quantified"]},{"year":2006,"claim":"Connected LIMK2 to mitosis, showing spindle/midzone localization and activation upon mitotic arrest, distinct from LIMK1.","evidence":"Cell synchronization, in vitro kinase assay, and immunofluorescence","pmids":["16455074"],"confidence":"Medium","gaps":["Trigger for mitotic hyperphosphorylation undefined here","Mitotic substrate identity not resolved"]},{"year":2008,"claim":"Demonstrated ROCK1 preferentially activates LIMK2 in a migration-mode-specific manner, refining which migratory programs use this kinase.","evidence":"FRET live-cell imaging of direct interaction and substrate phosphorylation in polarized vs blebbing cells","pmids":["18852895"],"confidence":"Medium","gaps":["Structural basis of ROCK1 preference for LIMK2 unknown","In vivo relevance of mode specificity untested"]},{"year":2010,"claim":"Identified LIMK2 as a p53 transcriptional target mediating survival after DNA damage, expanding its role beyond cytoskeletal control.","evidence":"siRNA, pharmacological LIMK inhibition, p53 target validation, and viability assays","pmids":["21079653"],"confidence":"Medium","gaps":["Downstream survival effector of LIMK2 not defined","Whether survival is cofilin-dependent unclear"]},{"year":2012,"claim":"Revealed reciprocal Aurora A–LIMK2 phosphorylation and a positive-feedback loop required for Aurora-A-driven tumorigenesis, establishing LIMK2 as a mitotic oncogenic node.","evidence":"Analog-sensitive Aurora A chemical genetics, in vitro kinase assay, mutagenesis, and xenograft","pmids":["22492986"],"confidence":"High","gaps":["Mechanism by which LIMK2 raises Aurora A levels unresolved","Relative contribution of each phosphosite not dissected"]},{"year":2012,"claim":"Established a cofilin-independent mitotic function: LIMK2 regulates astral microtubules and spindle orientation via TPPP downstream of RhoA-ROCK.","evidence":"RNAi epistasis and immunofluorescence of microtubules and spindle orientation","pmids":["22328514"],"confidence":"Medium","gaps":["Whether LIMK2 directly phosphorylates TPPP not shown","Coupling to actin-based mitotic roles unclear"]},{"year":2012,"claim":"Showed NF1 SecPH domain physically binds and inhibits LIMK2 by blocking ROCK activation, providing a direct molecular link between Ras and Rho/ROCK/LIMK2 signaling.","evidence":"Yeast two-hybrid, co-IP, and in vitro kinase inhibition assay","pmids":["23082153"],"confidence":"Medium","gaps":["Structural interface of NF1-LIMK2 undefined","Specificity over LIMK1 mechanism not explained"]},{"year":2012,"claim":"Genetically proved the LIMK2-cofilin axis is required in vivo for keratinocyte F-actin nucleation and migration during eyelid development.","evidence":"LIMK2 knockout mouse with F-actin and phospho-cofilin immunofluorescence and eyes-open-at-birth phenotype","pmids":["23071748"],"confidence":"High","gaps":["Redundancy with LIMK1 in other tissues not assessed","Upstream activator in keratinocytes not identified"]},{"year":2013,"claim":"Extended LIMK2 microtubule regulation to drug sensitivity, linking it to microtubule acetylation and TPPP1 in neuroblastoma.","evidence":"siRNA, drug sensitivity and cell cycle assays, Western blot","pmids":["23991158"],"confidence":"Medium","gaps":["Direct molecular control of acetylation unclear","Mechanism distinguishing actin vs microtubule roles undefined"]},{"year":2013,"claim":"Demonstrated LIMK2 transduces Sema3A chemorepulsion in migrating cortical interneurons, defining a developmental neuronal guidance role.","evidence":"siRNA, chemotactic assays, brain slices, in utero electroporation","pmids":["23519094"],"confidence":"Medium","gaps":["Receptor-to-LIMK2 signaling steps not mapped","Substrate downstream of LIMK2 in interneurons unidentified"]},{"year":2013,"claim":"Identified a tumor-constraining role: Limk2 deletion enlarges colon tumors and increases GI stem cell proliferation, conserved with Drosophila.","evidence":"Limk2 knockout colitis-associated CRC model and immunostaining","pmids":["23585469"],"confidence":"Medium","gaps":["Substrate mediating stem-cell restraint unknown","Reconciliation with oncogenic roles context-dependence unresolved"]},{"year":2017,"claim":"Placed LIMK2 downstream of BMPR2 via RhoA/ROCK and as a direct BMPR2 interactor driving osteosarcoma invasion and metastasis.","evidence":"iTRAQ phosphoproteomics, co-IP, and in vitro/in vivo invasion assays","pmids":["28938584"],"confidence":"Medium","gaps":["Direct LIMK2 substrate in this context not defined","BMPR2-LIMK2 binding interface unknown"]},{"year":2018,"claim":"Defined the LIMK2-1 isoform as a non-canonical effector that inhibits PP1 toward cofilin rather than phosphorylating cofilin directly.","evidence":"In vitro kinase and PP1 activity assays, co-IP, and stress fiber imaging","pmids":["30373762"],"confidence":"High","gaps":["Kinase function of LIMK2-1, if any, not assigned a substrate","Physiological context of isoform expression unclear"]},{"year":2019,"claim":"Established the LIMK2-TWIST1 axis: direct phosphorylation stabilizes TWIST1 in a mutual stabilization loop driving EMT and tumor formation in CRPC.","evidence":"Chemical genetic substrate ID, in vitro kinase assay, mutagenesis, ubiquitylation assay, xenograft","pmids":["30716360"],"confidence":"High","gaps":["Phosphosite-level mechanism of degradation protection partial","Generality beyond CRPC not tested here"]},{"year":2019,"claim":"Showed LIMK2 is required in vivo for platelet cytoskeletal function, hemostasis, and thrombus formation.","evidence":"LIMK2a knockout mouse, platelet spreading, aggregation, and thrombus assays","pmids":["31926945"],"confidence":"Medium","gaps":["Whether effect is solely cofilin-mediated not shown","Upstream platelet activator of LIMK2 not defined"]},{"year":2020,"claim":"Identified PTEN as a direct LIMK2 substrate, linking hypoxia to PTEN degradation and PI3K/AKT activation in CRPC within a reciprocal degradation loop.","evidence":"In vitro kinase assay, mutagenesis, ubiquitylation, PTEN knockout mouse, xenograft","pmids":["32931887"],"confidence":"High","gaps":["E3 ligase mediating PTEN degradation not identified","Phosphosite stoichiometry in vivo unquantified"]},{"year":2020,"claim":"Established LIMK2 degrades SPOP by direct phosphorylation, stabilizing AR, ARv7, and c-Myc to drive tumorigenesis.","evidence":"In vitro kinase assay, phospho-resistant SPOP mutagenesis, ubiquitylation assay, xenograft","pmids":["33311589"],"confidence":"High","gaps":["Ligase coupling SPOP phosphorylation to ubiquitylation undefined","Crosstalk with other LIMK2 substrates not integrated"]},{"year":2020,"claim":"Identified SRPK1 as a LIMK2 substrate whose inhibition phenocopies LIMK2 loss in blocking TNBC metastasis.","evidence":"SILAC phosphoproteomics, shRNA, pharmacological inhibition, in vivo metastasis model","pmids":["32859889"],"confidence":"Medium","gaps":["SRPK1 phosphosite(s) not mapped here","Downstream splicing effectors not defined"]},{"year":2021,"claim":"Added NKX3.1 as a directly phosphorylated, degraded LIMK2 substrate in a reciprocal loop regulating AR and AKT signaling.","evidence":"In vitro kinase assay, co-IP, ubiquitylation assay, xenograft","pmids":["34066036"],"confidence":"Medium","gaps":["Mechanism of mRNA downregulation unresolved","Phosphosites not individually validated functionally"]},{"year":2021,"claim":"Demonstrated the LIMK2-cofilin axis is required in vivo for airway smooth muscle contractile force and actin polymerization in a stimulus-specific manner.","evidence":"LIMK2 knockout mouse, force measurements, F/G-actin ratio, phospho-cofilin blot","pmids":["34353741"],"confidence":"High","gaps":["Basis of 5-HT vs acetylcholine specificity unknown","Upstream receptor-to-LIMK2 link not mapped"]},{"year":2021,"claim":"Showed LIMK2 directs definitive endoderm versus neuroectoderm fate in hESCs through cofilin-dependent actin and EMT-gene control.","evidence":"siRNA, F-actin and p-cofilin assays, lineage marker RT-PCR","pmids":["33977398"],"confidence":"Medium","gaps":["Transcriptional link to fate genes not defined","Whether non-cofilin substrates contribute untested"]},{"year":2022,"claim":"Placed LIMK2 in a Gα13-RhoA/C-ROCK pathway downstream of the TP receptor that restrains endothelial angiogenic sprouting.","evidence":"RNAi, pharmacological inhibition, spheroid sprouting, RhoA/C FRET biosensors","pmids":["35525325"],"confidence":"Medium","gaps":["Direct LIMK2 substrate in endothelial sprouting not shown","Relationship to focal-adhesion regulation mechanistic detail limited"]},{"year":2023,"claim":"Identified the LIMK2→G3BP1→ESM1 pathway driving melanoma growth and metastasis via mRNA stabilization.","evidence":"Phosphoproteomics, shRNA, RNA-seq, rescue experiments, in vivo tumor models","pmids":["36922679"],"confidence":"Medium","gaps":["G3BP1 phosphosite and consequence not detailed here","How phosphorylation alters ESM1 mRNA stability unclear"]},{"year":2025,"claim":"Defined a LIMK2-MST4-NPM1 cascade controlling centrosome clustering, explaining how LIMK2 supports mitotic fidelity in tumor cells.","evidence":"In vitro kinase assay, mutagenesis, co-IP, shRNA, xenograft and 4NQO mouse models","pmids":["40775397"],"confidence":"High","gaps":["Integration with TPPP-based spindle role unresolved","Whether MST4 activation occurs in non-cancer mitosis untested"]},{"year":2025,"claim":"Characterized LIMK2-1 as a PKC-activated, CPI-17-like inhibitor of PP1c and myosin phosphatase with nanomolar potency, defining a phosphatase-regulatory mode for this isoform.","evidence":"Overexpression, co-IP with PP1c, in vitro phosphatase assay with IC50, phosphospecific antibody","pmids":["40806479"],"confidence":"High","gaps":["Physiological signaling context regulating LIMK2-1 unknown","Endogenous expression and abundance not quantified"]},{"year":null,"claim":"How LIMK2 selects between its canonical cofilin/cytoskeletal output and its diverse non-cytoskeletal substrate program (TWIST1, PTEN, SPOP, NKX3.1, SRPK1, G3BP1, MST4) in a given cell context remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying determinant of substrate choice identified","Structural basis of substrate recognition undefined","Reconciliation of tumor-suppressive and oncogenic roles incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3,8,17,18,19,24]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,11,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,2,3]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,6,15,28]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,8,9,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[17,18,19,20,23,24]}],"complexes":[],"partners":["ROCK1","PP1","NF1","BMPR2","TWIST1","MST4","SPOP","NKX3.1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P53671","full_name":"LIM domain kinase 2","aliases":[],"length_aa":638,"mass_kda":72.2,"function":"Serine/threonine-protein kinase that plays an essential role in the regulation of actin filament dynamics (PubMed:10436159, PubMed:11018042). Acts downstream of several Rho family GTPase signal transduction pathways (PubMed:10436159, PubMed:11018042). Involved in astral microtubule organization and mitotic spindle orientation during early stages of mitosis by mediating phosphorylation of TPPP (PubMed:22328514). Displays serine/threonine-specific phosphorylation of myelin basic protein and histone (MBP) in vitro (PubMed:8537403). Suppresses ciliogenesis via multiple pathways; phosphorylation of CFL1, suppression of directional trafficking of ciliary vesicles to the ciliary base, and by facilitating YAP1 nuclear localization where it acts as a transcriptional corepressor of the TEAD4 target genes AURKA and PLK1 (PubMed:25849865)","subcellular_location":"Cytoplasm; Cytoplasm, perinuclear region; Nucleus","url":"https://www.uniprot.org/uniprotkb/P53671/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LIMK2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000182541","cell_line_id":"CID001190","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":1}],"interactors":[{"gene":"CDC37","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001190","total_profiled":1310},"omim":[{"mim_id":"607621","title":"COLLECTIN 12; COLEC12","url":"https://www.omim.org/entry/607621"},{"mim_id":"604746","title":"TESTIS-ASSOCIATED ACTIN-MODELING KINASE 2; TESK2","url":"https://www.omim.org/entry/604746"},{"mim_id":"601988","title":"LIM DOMAIN KINASE 2; LIMK2","url":"https://www.omim.org/entry/601988"},{"mim_id":"601782","title":"TESTIS-ASSOCIATED ACTIN-MODELING KINASE 1; TESK1","url":"https://www.omim.org/entry/601782"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LIMK2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P53671","domains":[{"cath_id":"2.10.110.10","chopping":"11-67","consensus_level":"high","plddt":84.3586,"start":11,"end":67},{"cath_id":"2.30.42.10","chopping":"84-242","consensus_level":"medium","plddt":86.2718,"start":84,"end":242},{"cath_id":"3.30.200.20","chopping":"324-405","consensus_level":"high","plddt":80.1312,"start":324,"end":405},{"cath_id":"1.10.510.10","chopping":"410-476_503-629","consensus_level":"high","plddt":92.5202,"start":410,"end":629}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P53671","model_url":"https://alphafold.ebi.ac.uk/files/AF-P53671-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P53671-F1-predicted_aligned_error_v6.png","plddt_mean":76.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LIMK2","jax_strain_url":"https://www.jax.org/strain/search?query=LIMK2"},"sequence":{"accession":"P53671","fasta_url":"https://rest.uniprot.org/uniprotkb/P53671.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P53671/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P53671"}},"corpus_meta":[{"pmid":"7651734","id":"PMC_7651734","title":"LIMK-1 and LIMK-2, two members of a LIM motif-containing protein kinase family.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7651734","citation_count":86,"is_preprint":false},{"pmid":"20047470","id":"PMC_20047470","title":"LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells.","date":"2009","source":"Zebrafish","url":"https://pubmed.ncbi.nlm.nih.gov/20047470","citation_count":82,"is_preprint":false},{"pmid":"30886151","id":"PMC_30886151","title":"Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30886151","citation_count":68,"is_preprint":false},{"pmid":"21079653","id":"PMC_21079653","title":"p53-mediated transcriptional regulation and activation of the actin cytoskeleton regulatory RhoC to LIMK2 signaling pathway promotes cell survival.","date":"2010","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21079653","citation_count":68,"is_preprint":false},{"pmid":"16169856","id":"PMC_16169856","title":"The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169856","citation_count":63,"is_preprint":false},{"pmid":"31695759","id":"PMC_31695759","title":"NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31695759","citation_count":54,"is_preprint":false},{"pmid":"22492986","id":"PMC_22492986","title":"LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22492986","citation_count":51,"is_preprint":false},{"pmid":"9149099","id":"PMC_9149099","title":"Comparison of tissue distribution of two novel serine/threonine kinase genes containing the LIM motif (LIMK-1 and LIMK-2) in the developing rat.","date":"1997","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9149099","citation_count":49,"is_preprint":false},{"pmid":"36899941","id":"PMC_36899941","title":"LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36899941","citation_count":46,"is_preprint":false},{"pmid":"16455074","id":"PMC_16455074","title":"Different activity regulation and subcellular localization of LIMK1 and LIMK2 during cell cycle transition.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16455074","citation_count":37,"is_preprint":false},{"pmid":"32859889","id":"PMC_32859889","title":"LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1.","date":"2020","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32859889","citation_count":35,"is_preprint":false},{"pmid":"29970879","id":"PMC_29970879","title":"Imbalanced LIMK1 and LIMK2 expression leads to human colorectal cancer progression and metastasis via promoting β-catenin nuclear translocation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29970879","citation_count":34,"is_preprint":false},{"pmid":"23082153","id":"PMC_23082153","title":"Nf1 RasGAP inhibition of LIMK2 mediates a new cross-talk between Ras and Rho pathways.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23082153","citation_count":34,"is_preprint":false},{"pmid":"30716360","id":"PMC_30716360","title":"Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30716360","citation_count":32,"is_preprint":false},{"pmid":"22328514","id":"PMC_22328514","title":"TPPP acts downstream of RhoA-ROCK-LIMK2 to regulate astral microtubule organization and spindle orientation.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22328514","citation_count":31,"is_preprint":false},{"pmid":"33014879","id":"PMC_33014879","title":"VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33014879","citation_count":30,"is_preprint":false},{"pmid":"23585469","id":"PMC_23585469","title":"Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation.","date":"2013","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/23585469","citation_count":29,"is_preprint":false},{"pmid":"25593987","id":"PMC_25593987","title":"Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model.","date":"2014","source":"Oncoscience","url":"https://pubmed.ncbi.nlm.nih.gov/25593987","citation_count":29,"is_preprint":false},{"pmid":"8954941","id":"PMC_8954941","title":"Subcellular localization and protein interaction of the human LIMK2 gene expressing alternative transcripts with tissue-specific regulation.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8954941","citation_count":28,"is_preprint":false},{"pmid":"30006972","id":"PMC_30006972","title":"LIMK2 acts as an oncogene in bladder cancer and its functional SNP in the microRNA-135a binding site affects bladder cancer risk.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30006972","citation_count":27,"is_preprint":false},{"pmid":"16524786","id":"PMC_16524786","title":"Upregulation of profilin, cofilin-2 and LIMK2 in cultured pulmonary artery smooth muscle cells and in pulmonary arteries of monocrotaline-treated rats.","date":"2006","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16524786","citation_count":26,"is_preprint":false},{"pmid":"28938584","id":"PMC_28938584","title":"BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28938584","citation_count":25,"is_preprint":false},{"pmid":"31072327","id":"PMC_31072327","title":"MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31072327","citation_count":25,"is_preprint":false},{"pmid":"15923181","id":"PMC_15923181","title":"Inhibition of nuclear import of LIMK2 in endothelial cells by protein kinase C-dependent phosphorylation at Ser-283.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15923181","citation_count":25,"is_preprint":false},{"pmid":"15467300","id":"PMC_15467300","title":"PDGF and IL-1beta upregulate cofilin and LIMK2 in canine cultured pulmonary artery smooth muscle cells.","date":"2004","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/15467300","citation_count":23,"is_preprint":false},{"pmid":"31319858","id":"PMC_31319858","title":"LIMK1 and LIMK2 regulate cortical development through affecting neural progenitor cell proliferation and migration.","date":"2019","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/31319858","citation_count":22,"is_preprint":false},{"pmid":"9425257","id":"PMC_9425257","title":"cDNA cloning, genomic organization, and chromosomal localization of the mouse LIM motif-containing kinase gene, Limk2.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9425257","citation_count":22,"is_preprint":false},{"pmid":"34066036","id":"PMC_34066036","title":"LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34066036","citation_count":20,"is_preprint":false},{"pmid":"32931887","id":"PMC_32931887","title":"Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32931887","citation_count":20,"is_preprint":false},{"pmid":"26438559","id":"PMC_26438559","title":"Endothelin-1 induces LIMK2-mediated programmed necrotic neuronal death independent of NOS activity.","date":"2015","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/26438559","citation_count":20,"is_preprint":false},{"pmid":"33311589","id":"PMC_33311589","title":"Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.","date":"2020","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33311589","citation_count":20,"is_preprint":false},{"pmid":"23071748","id":"PMC_23071748","title":"Keratinocyte migration in the developing eyelid requires LIMK2.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23071748","citation_count":20,"is_preprint":false},{"pmid":"23991158","id":"PMC_23991158","title":"LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23991158","citation_count":20,"is_preprint":false},{"pmid":"10452946","id":"PMC_10452946","title":"Cloning and characterization of the alternative promoter regions of the human LIMK2 gene responsible for alternative transcripts with tissue-specific expression.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/10452946","citation_count":20,"is_preprint":false},{"pmid":"30833597","id":"PMC_30833597","title":"Deletion of Limk1 and Limk2 in mice does not alter cochlear development or auditory function.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30833597","citation_count":19,"is_preprint":false},{"pmid":"18852895","id":"PMC_18852895","title":"ROCK1 and LIMK2 interact in spread but not blebbing cancer cells.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18852895","citation_count":18,"is_preprint":false},{"pmid":"25549868","id":"PMC_25549868","title":"Inhibition of FSS-induced actin cytoskeleton reorganization by silencing LIMK2 gene increases the mechanosensitivity of primary osteoblasts.","date":"2014","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25549868","citation_count":17,"is_preprint":false},{"pmid":"18805530","id":"PMC_18805530","title":"Effect of LIMK2 RNAi on reorganization of the actin cytoskeleton in osteoblasts induced by fluid shear stress.","date":"2008","source":"Journal of biomechanics","url":"https://pubmed.ncbi.nlm.nih.gov/18805530","citation_count":17,"is_preprint":false},{"pmid":"9089416","id":"PMC_9089416","title":"Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.","date":"1997","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9089416","citation_count":16,"is_preprint":false},{"pmid":"23881296","id":"PMC_23881296","title":"Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.","date":"2013","source":"Molecular bioSystems","url":"https://pubmed.ncbi.nlm.nih.gov/23881296","citation_count":15,"is_preprint":false},{"pmid":"23519094","id":"PMC_23519094","title":"Limk2 mediates semaphorin signalling in cortical interneurons migrating through the subpallium.","date":"2013","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/23519094","citation_count":13,"is_preprint":false},{"pmid":"30373762","id":"PMC_30373762","title":"LIMK2-1, a new isoform of human LIMK2, regulates actin cytoskeleton remodeling via a different signaling pathway than that of its two homologs, LIMK2a and LIMK2b.","date":"2018","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30373762","citation_count":12,"is_preprint":false},{"pmid":"36922679","id":"PMC_36922679","title":"LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36922679","citation_count":11,"is_preprint":false},{"pmid":"37946061","id":"PMC_37946061","title":"Stratifin (SFN) Regulates Cervical Cancer Cell Proliferation, Apoptosis, and Cytoskeletal Remodeling and Metastasis Progression Through LIMK2/Cofilin Signaling.","date":"2023","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37946061","citation_count":11,"is_preprint":false},{"pmid":"32141548","id":"PMC_32141548","title":"Metabolites of intestinal microflora upregulate miR-192-5p to suppress proliferation of colon cancer cells via RhoA-ROCK-LIMK2 pathway.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32141548","citation_count":11,"is_preprint":false},{"pmid":"37141984","id":"PMC_37141984","title":"LIMK2: A Multifaceted kinase with pleiotropic roles in human physiology and pathologies.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37141984","citation_count":9,"is_preprint":false},{"pmid":"30870492","id":"PMC_30870492","title":"Chronic administration of LIMK2 inhibitors alleviates cavernosal veno-occlusive dysfunction through suppression of cavernosal fibrosis in a rat model of erectile dysfunction after cavernosal nerve injury.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30870492","citation_count":9,"is_preprint":false},{"pmid":"31926945","id":"PMC_31926945","title":"LIM kinase 2 (LIMK2) may play an essential role in platelet function.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31926945","citation_count":8,"is_preprint":false},{"pmid":"35525325","id":"PMC_35525325","title":"Thromboxane A2 receptor activation via Gα13-RhoA/C-ROCK-LIMK2-dependent signal transduction inhibits angiogenic sprouting of human endothelial cells.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35525325","citation_count":8,"is_preprint":false},{"pmid":"30594563","id":"PMC_30594563","title":"LIMK2-1 is a Hominidae-Specific Isoform of LIMK2 Expressed in Central Nervous System and Associated with Intellectual Disability.","date":"2018","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30594563","citation_count":6,"is_preprint":false},{"pmid":"38580197","id":"PMC_38580197","title":"Decoding the tumour-modulatory roles of LIMK2.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38580197","citation_count":5,"is_preprint":false},{"pmid":"34353741","id":"PMC_34353741","title":"LIMK2 is required for membrane cytoskeleton reorganization of contracting airway smooth muscle.","date":"2021","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/34353741","citation_count":5,"is_preprint":false},{"pmid":"32124389","id":"PMC_32124389","title":"mRNA level of ROCK1, RHOA, and LIMK2 as genes associated with apoptosis in evaluation of effectiveness of adalimumab treatment.","date":"2020","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/32124389","citation_count":5,"is_preprint":false},{"pmid":"33977398","id":"PMC_33977398","title":"Involvement of LIMK2 in actin cytoskeleton remodeling during the definitive endoderm differentiation.","date":"2021","source":"In vitro cellular & developmental biology. Animal","url":"https://pubmed.ncbi.nlm.nih.gov/33977398","citation_count":5,"is_preprint":false},{"pmid":"39631222","id":"PMC_39631222","title":"Unveiling novel type 1 inhibitors for targeting LIM kinase 2 (LIMK2) for cancer therapeutics: An integrative pharmacoinformatics approach.","date":"2024","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39631222","citation_count":3,"is_preprint":false},{"pmid":"37077345","id":"PMC_37077345","title":"NUDT21 relieves sevoflurane-induced neurological damage in rats by down-regulating LIMK2.","date":"2023","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37077345","citation_count":3,"is_preprint":false},{"pmid":"36330887","id":"PMC_36330887","title":"Function of connexin 43 and RhoA/LIMK2/Cofilin signaling pathway in transient changes of contraction and dilation of human umbilical arterial smooth muscle cells.","date":"2022","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36330887","citation_count":2,"is_preprint":false},{"pmid":"20193279","id":"PMC_20193279","title":"[Effects of LIMK2 RNA interference on the mechanosensitivity of c-fos gene in osteoblast].","date":"2009","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/20193279","citation_count":1,"is_preprint":false},{"pmid":"38063080","id":"PMC_38063080","title":"Harnessing allosteric inhibition: prioritizing LIMK2 inhibitors for targeted cancer therapy through pharmacophore-based virtual screening and essential molecular dynamics.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/38063080","citation_count":1,"is_preprint":false},{"pmid":"9556220","id":"PMC_9556220","title":"A sequence highly similar to PNG is located on chromosome 22q12 in intron 15 of the LIMK-2 gene.","date":"1998","source":"Biochemistry and molecular biology international","url":"https://pubmed.ncbi.nlm.nih.gov/9556220","citation_count":1,"is_preprint":false},{"pmid":"40775397","id":"PMC_40775397","title":"LIMK2 promotes centrosome clustering and cancer progression by activating MST4-mediated phosphorylation of NPM1.","date":"2025","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/40775397","citation_count":0,"is_preprint":false},{"pmid":"40806479","id":"PMC_40806479","title":"LIMK2-1 Is a Phosphorylation-Dependent Inhibitor of Protein Phosphatase-1 Catalytic Subunit and Myosin Phosphatase Holoenzyme.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806479","citation_count":0,"is_preprint":false},{"pmid":"42066056","id":"PMC_42066056","title":"Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.","date":"2026","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/42066056","citation_count":0,"is_preprint":false},{"pmid":"41644972","id":"PMC_41644972","title":"LIMK2 inactivation suppresses mechanical stimulation-induced dermal fibroblast differentiation and resistance to apoptosis.","date":"2026","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41644972","citation_count":0,"is_preprint":false},{"pmid":"41680856","id":"PMC_41680856","title":"Ift46 deficiency causes renal cyst via enhanced Limk2 through lack of autophagy flux.","date":"2026","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/41680856","citation_count":0,"is_preprint":false},{"pmid":"42185554","id":"PMC_42185554","title":"Rare variants in TTC7A, ROCK2 and LIMK2 suggest a role for the ROCK-signaling pathway in isolated intestinal malrotation.","date":"2026","source":"Pediatric surgery international","url":"https://pubmed.ncbi.nlm.nih.gov/42185554","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.17.649341","title":"Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors","date":"2025-04-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.17.649341","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34748,"output_tokens":6720,"usd":0.102522,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15754,"output_tokens":7247,"usd":0.129972,"stage2_stop_reason":"end_turn"},"total_usd":0.232494,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"LIMK2 is a serine/threonine kinase containing two N-terminal LIM motifs and a C-terminal kinase domain; it phosphorylates serine and threonine residues of myelin basic protein in vitro, demonstrating its catalytic activity.\",\n      \"method\": \"In vitro kinase assay, immunoprecipitation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay demonstrated catalytic activity, single lab, single method\",\n      \"pmids\": [\"7651734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"LIMK2a (two LIM domains + PDZ + kinase) localizes to both cytoplasm and nucleus, while LIMK2b (one and half LIM domains) localizes mainly to cytoplasm; a truncated LIMK2-Kinase construct localizes to the nucleus. LIMK2a and LIMK2b associate with 63-kDa and 58-kDa partner proteins, respectively.\",\n      \"method\": \"Transfection studies, subcellular fractionation, immunofluorescence, co-precipitation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — direct localization experiment with co-precipitation, single lab, single study\",\n      \"pmids\": [\"8954941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Recombinant LIMK2 exhibits autophosphorylation and serine/threonine kinase activity toward exogenous substrate MBP; endogenous LIMK2 co-precipitates with a 140 kDa tyrosine-phosphorylated protein but is not itself tyrosine phosphorylated; LIMK2 localizes in both the nucleus and a Triton X-100 soluble cytoplasmic fraction.\",\n      \"method\": \"In vitro kinase assay, stable transfection, co-precipitation, subcellular fractionation\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — in vitro kinase assay with co-precipitation, single lab\",\n      \"pmids\": [\"9089416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PKC-delta phosphorylates LIMK2 at Ser-283 in vitro and in endothelial cells; phosphorylation at Ser-283 (but not Thr-494) inhibits nuclear import of LIMK2, retaining it in the cytoplasm. This cytoplasmic retention is associated with relief of LIMK2-mediated suppression of cyclin D1 expression and promotion of G1-to-S phase transition.\",\n      \"method\": \"EGFP-LIMK2 live imaging, FRAP, leptomycin B treatment, site-directed mutagenesis, in vitro kinase assay, immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus mutagenesis plus live-cell FRAP imaging, multiple orthogonal methods in single study\",\n      \"pmids\": [\"15923181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Loss of neurofibromin activates a Rho-ROCK-LIMK2 pathway that elevates cofilin phosphorylation, promoting actin stress fiber formation and enhanced cell motility; this pathway requires Ras activation but is independent of Raf, PI3K, and RalGEF downstream pathways.\",\n      \"method\": \"siRNA knockdown, Western blot for phospho-cofilin, genetic epistasis with NF1-GRD re-expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via siRNA + rescue experiment, single lab, multiple pathway controls\",\n      \"pmids\": [\"16169856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LIMK2 activity toward cofilin does not change during normal cell division but is markedly increased when cells are arrested at mitosis by nocodazole-induced microtubule disruption, accompanied by LIMK2 hyperphosphorylation. LIMK2 localizes to the mitotic spindle during prometaphase through anaphase and to the spindle midzone during anaphase–telophase, distinct from LIMK1.\",\n      \"method\": \"Cell synchronization, in vitro kinase assay, immunofluorescence microscopy\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct kinase activity assay combined with immunofluorescence localization, single lab\",\n      \"pmids\": [\"16455074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ROCK1 preferentially phosphorylates LIMK2 over LIMK1; direct ROCK1–LIMK2 interaction detected by FRET occurs in polarized (spread) but not blebbing cancer cells, indicating the ROCK1:LIMK2 pathway is specific to mesenchymal-mode rather than amoeboid-mode migration.\",\n      \"method\": \"FRET live-cell imaging, substrate phosphorylation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — novel FRET data for direct interaction, single lab\",\n      \"pmids\": [\"18852895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RhoC and LIMK2 are direct transcriptional targets of p53 induced by genotoxic agents; LIMK2 activation downstream of p53 promotes cell survival following DNA damage, and LIMK inhibition sensitizes cells to radio- and chemotherapy.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibition, ChIP/reporter assays (p53 target gene identification), cell viability assays\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA + pharmacological inhibition + direct p53 target validation, single lab, multiple methods\",\n      \"pmids\": [\"21079653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Aurora A kinase directly phosphorylates LIMK2 at S283, T494, and T505, regulating LIMK2 kinase activity, subcellular localization, and protein levels. LIMK2 in turn positively regulates Aurora A levels, forming a positive-feedback loop. LIMK2 ablation fully abrogates Aurora-A-mediated tumorigenesis in vivo.\",\n      \"method\": \"Chemical genetic approach (analog-sensitive Aurora A), in vitro kinase assay, site-directed mutagenesis, xenograft mouse model, Western blot\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chemical genetic substrate identification plus in vitro kinase assay plus mutagenesis plus in vivo rescue, multiple orthogonal methods\",\n      \"pmids\": [\"22492986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LIMK2 acts downstream of RhoA-ROCK to regulate astral microtubule organization through TPPP (tubulin polymerization promoting protein), independently of cofilin, during mitosis; this pathway controls spindle orientation in mitotic cells.\",\n      \"method\": \"RNAi knockdown, epistasis analysis, immunofluorescence for microtubules and spindle orientation\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi epistasis with multiple proteins, single lab, immunofluorescence readout\",\n      \"pmids\": [\"22328514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Nf1 RasGAP SecPH domain physically interacts with LIMK2 (but not LIMK1), partially inhibiting LIMK2 kinase activity toward cofilin by preventing ROCK-mediated activation of LIMK2, thereby connecting Ras and Rho/ROCK/LIMK2/cofilin signaling.\",\n      \"method\": \"Yeast two-hybrid screening, co-immunoprecipitation, in vitro kinase assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP plus in vitro kinase inhibition assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"23082153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In LIMK2 knockout mice, keratinocytes fail to nucleate filamentous actin and remain immobile during eyelid development, resulting in eyes open at birth phenotype; this is associated with markedly reduced phospho-cofilin levels, demonstrating that LIMK2 activity and cofilin phosphorylation are required for keratinocyte migration in vivo.\",\n      \"method\": \"Knockout mouse model, immunofluorescence for F-actin and phospho-cofilin, phenotypic analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined in vivo cellular phenotype and molecular readout (p-cofilin), single lab\",\n      \"pmids\": [\"23071748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LIMK2 depletion sensitizes neuroblastoma cells to microtubule-targeted drugs by enhancing cell cycle arrest and apoptosis; LIMK2 modulates microtubule acetylation and levels of TPPP1, suggesting a role in regulating the microtubule network independent of actin/cofilin.\",\n      \"method\": \"siRNA knockdown, drug sensitivity assays, cell cycle analysis, Western blot for microtubule acetylation and TPPP1\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA with multiple functional readouts, single lab\",\n      \"pmids\": [\"23991158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Limk2 mediates Sema3A (but not Sema3F) chemorepulsive signaling in cortical interneurons migrating through the subpallium; Limk2-siRNA-transfected interneurons fail to respond to Sema3A and aberrantly invade the developing striatum.\",\n      \"method\": \"siRNA knockdown, chemotactic assay, brain slice preparations, in utero electroporation\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA in multiple experimental systems (chemotaxis + brain slice + in utero electroporation), single lab\",\n      \"pmids\": [\"23519094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Limk2 deletion in mice increases colon tumor size in a colitis-associated colorectal cancer model and increases gastrointestinal stem cell proliferation, demonstrating a conserved role for LIMK2 in constraining stem cell proliferation.\",\n      \"method\": \"Limk2 knockout mouse model, colitis-associated CRC model, immunostaining for LIMK2 expression and substrate phosphorylation\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined in vivo phenotype, cross-validated with Drosophila genetic analysis, single lab\",\n      \"pmids\": [\"23585469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BMPR2 activates LIMK2 through the RhoA/ROCK pathway and also interacts directly with LIMK2; activated LIMK2 promotes phosphorylation of downstream signaling components driving osteosarcoma invasion and metastasis.\",\n      \"method\": \"iTRAQ-based phosphoproteomics, Western blot, co-immunoprecipitation, in vitro and in vivo invasion/metastasis assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics plus co-IP plus functional validation, single lab\",\n      \"pmids\": [\"28938584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The LIMK2-1 isoform contains a C-terminal PP1 inhibitory domain absent in LIMK2a and LIMK2b. LIMK2-1 does not phosphorylate cofilin directly despite having kinase activity; instead it interacts with PP1 and partially inhibits PP1 activity toward cofilin, thereby indirectly maintaining phospho-cofilin levels and promoting actin stress fiber formation.\",\n      \"method\": \"Biochemical characterization, in vitro kinase assay, co-immunoprecipitation with PP1, PP1 activity assay, actin stress fiber imaging\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus PP1 activity assay plus co-IP plus mutagenesis analysis, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"30373762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LIMK2 directly phosphorylates TWIST1, stabilizing it by preventing its degradation; TWIST1 in turn stabilizes LIMK2 by inhibiting its ubiquitylation. Phosphorylation-dead TWIST1 acts as dominant negative and fully prevents EMT and tumor formation in vivo, establishing the LIMK2-TWIST1 signaling axis in CRPC.\",\n      \"method\": \"Chemical genetic substrate identification, in vitro kinase assay, site-directed mutagenesis, xenograft mouse model, ubiquitylation assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct phosphorylation validated with mutagenesis and in vivo dominant-negative rescue, multiple orthogonal methods\",\n      \"pmids\": [\"30716360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LIMK2 phosphorylates PTEN at five sites, degrading it and inhibiting its activity, thereby activating PI3K/AKT oncogenic signaling. PTEN also degrades LIMK2 in a feedback loop (confirmed in PTEN-/- vs PTEN+/+ mouse prostates), identifying LIMK2 as the missing link between hypoxia and PTEN degradation in CRPC.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, ubiquitylation assay, PTEN knockout mouse validation, xenograft model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct phosphorylation with mutagenesis plus in vivo mouse genetic validation plus in vitro biochemistry, multiple orthogonal methods\",\n      \"pmids\": [\"32931887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LIMK2 degrades SPOP by direct phosphorylation at three sites; SPOP promotes LIMK2 ubiquitylation in a feedback loop. LIMK2-mediated SPOP degradation stabilizes AR, ARv7, and c-Myc. Phospho-resistant SPOP completely suppresses tumorigenesis in vivo.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis (phospho-resistant SPOP), ubiquitylation assay, xenograft mouse model\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct phosphorylation with phospho-resistant mutagenesis rescue in vivo, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"33311589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LIMK2 inhibition blocks SRPK1 phosphorylation and its kinase activity; SRPK1 identified as a LIMK2 substrate by SILAC-based phosphoproteomics. Genetic or pharmacological inhibition of LIMK2 or SRPK1 equivalently blocks metastatic attributes of TNBC cells.\",\n      \"method\": \"SILAC-based phosphoproteomics, shRNA knockdown, pharmacological inhibition, in vivo metastasis mouse model\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics substrate identification with functional validation, single lab\",\n      \"pmids\": [\"32859889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LIMK2 directly phosphorylates NKX3.1, promoting its degradation in CRPC cells. NKX3.1 in turn promotes LIMK2 ubiquitylation. LIMK2 also downregulates NKX3.1 mRNA. LIMK2-NKX3.1 crosstalk regulates AR, ARv7, and AKT signaling.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, ubiquitylation assay, Western blot, xenograft mouse model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation assay plus ubiquitylation assay plus in vivo validation, single lab\",\n      \"pmids\": [\"34066036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LIMK2 phosphorylates cofilin to regulate F-actin dynamics in airway smooth muscle (ASM); LIMK2-deficient ASM shows ~30% inhibition of contractile force and reduced F/G-actin ratio. LIMK2 functions independently of cross-bridge movement and is required for 5-HT-evoked length-sensitive contraction but not acetylcholine-evoked contraction.\",\n      \"method\": \"LIMK2 knockout mouse, force measurements, F/G-actin ratio assay, phospho-cofilin Western blot\",\n      \"journal\": \"Journal of genetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with defined contractile phenotype and molecular readout, multiple functional assays\",\n      \"pmids\": [\"34353741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LIMK2 phosphorylates G3BP1, and G3BP1 is required for ESM1 mRNA stability. LIMK2→G3BP1→ESM1 pathway promotes melanoma tumor growth and metastasis; G3BP1 knockdown mirrors LIMK2 inhibition and ESM1 ectopic expression rescues LIMK2 or G3BP1 inhibition.\",\n      \"method\": \"Phosphoproteomics, shRNA knockdown, RNA-seq, rescue experiments, in vivo mouse tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics substrate identification with epistasis rescue, single lab\",\n      \"pmids\": [\"36922679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LIMK2 phosphorylates MST4 at T178, activating its kinase function; activated MST4 then phosphorylates NPM1 at T95, which is essential for centrosome clustering and tumor cell proliferation. LIMK2 knockout attenuates esophageal tumorigenesis in vivo; pharmacological LIMK2 inhibition disrupts centrosome clustering causing multipolar spindle assembly and apoptosis.\",\n      \"method\": \"In vitro kinase assay, site-directed mutagenesis, co-immunoprecipitation, shRNA knockdown, xenograft and 4NQO mouse tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct phosphorylation with mutagenesis validated by in vivo mouse models and pharmacological inhibition, multiple orthogonal methods\",\n      \"pmids\": [\"40775397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The LIMK2-1 isoform is phosphorylated predominantly by protein kinase C and, when phosphorylated, inhibits PP1 catalytic subunit (PP1c) isoforms and the myosin phosphatase (MP) holoenzyme with IC50 ~28–47 nM, functioning as a CPI-17-like phosphatase inhibitor. LIMK2-1 interacts with PP1c isoforms.\",\n      \"method\": \"Flag-LIMK2-1 overexpression, co-immunoprecipitation with PP1c, in vitro phosphatase activity assay, calyculin A treatment, phosphospecific antibody\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphatase assay with IC50 determination plus co-IP plus site-specific phosphorylation analysis, multiple orthogonal methods\",\n      \"pmids\": [\"40806479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LIMK2a knockout mice show prolonged bleeding after injury; LIMK2 protein is expressed in human and mouse platelets and LIMK2a-deficient mice exhibit impaired platelet spreading, aggregation, and thrombus formation, demonstrating a role for LIMK2 in platelet cytoskeletal function.\",\n      \"method\": \"LIMK2a knockout mouse, platelet spreading assay, aggregation assay, thrombus formation, Western blot\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse with multiple platelet functional readouts, single lab\",\n      \"pmids\": [\"31926945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LIMK2 depletion in human embryonic stem cells inhibits definitive endoderm generation and promotes neuroectodermal fate; knockdown reduces actin stress fiber assembly and cofilin phosphorylation, and impairs EMT-gene upregulation and cell migration during endodermal differentiation.\",\n      \"method\": \"siRNA knockdown, immunofluorescence for F-actin, Western blot for p-cofilin, RT-PCR for lineage markers\",\n      \"journal\": \"In vitro cellular & developmental biology. Animal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — siRNA with multiple readouts in hESC system, single lab\",\n      \"pmids\": [\"33977398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TP receptor activation signals through Gα13-RhoA/C-ROCK-LIMK2 to inhibit angiogenic sprouting of human endothelial cells; pharmacological ROCK or LIMK2 inhibition reverses TP-agonist-induced endothelial cell tension and focal adhesion dysregulation.\",\n      \"method\": \"RNAi gene silencing, pharmacological inhibition, HUVEC spheroid sprouting assay, FRET biosensors for RhoA/C activity, live-cell imaging\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi plus pharmacological inhibition plus FRET biosensors for upstream activators, single lab\",\n      \"pmids\": [\"35525325\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LIMK2 is a serine/threonine kinase that acts downstream of Rho GTPases (RhoA/C, RhoC) via ROCK1/2 and PAK to phosphorylate and inactivate cofilin, thereby stabilizing actin filaments and regulating cytoskeletal dynamics required for cell migration, mitosis, and mechanotransduction; its activity and nuclear-cytoplasmic shuttling are regulated by upstream phosphorylation events (PKC-delta at Ser-283, Aurora A at S283/T494/T505, ROCK at activating sites), and beyond cofilin it directly phosphorylates substrates including TWIST1, PTEN, SPOP, NKX3.1, MST4, and SRPK1 to promote context-dependent oncogenic or survival signaling; the LIMK2-1 isoform uniquely inhibits PP1 phosphatase in a PKC-phosphorylation-dependent manner rather than directly phosphorylating cofilin.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LIMK2 is a serine/threonine kinase, defined by N-terminal LIM motifs, a PDZ domain, and a C-terminal kinase domain, that integrates Rho-family GTPase signaling with actin cytoskeletal dynamics and cell cycle control [#0, #1]. Its canonical output is phosphorylation and inactivation of cofilin downstream of a RhoA/RhoC–ROCK module, stabilizing F-actin to drive cell migration and contractility; this axis is required in vivo for keratinocyte migration during eyelid closure, airway smooth muscle contraction, platelet spreading and thrombus formation, and endothelial responses [#11, #22, #26, #28]. ROCK1 preferentially activates LIMK2 over LIMK1 in a manner specific to mesenchymal-mode migration, and the pathway is constrained by neurofibromin, whose loss elevates cofilin phosphorylation and motility [#6, #5, #10]. LIMK2 activity and nuclear–cytoplasmic shuttling are tuned by upstream phosphorylation: PKC-delta phosphorylates Ser-283 to block nuclear import and relieve suppression of cyclin D1, while Aurora A phosphorylates S283/T494/T505 in a reciprocal positive-feedback loop essential for Aurora-A-driven tumorigenesis [#3, #8]. During mitosis LIMK2 localizes to the spindle and, downstream of RhoA-ROCK, regulates astral microtubule organization and spindle orientation through TPPP independently of cofilin, and supports centrosome clustering via an MST4–NPM1 cascade [#5, #9, #24]. As a p53 target, LIMK2 promotes survival after DNA damage [#7]. Beyond cofilin, LIMK2 directly phosphorylates a set of substrates—TWIST1, PTEN, SPOP, NKX3.1, SRPK1, G3BP1, and MST4—frequently within mutual stabilization/degradation feedback loops, to drive context-dependent oncogenic and EMT signaling in prostate, breast, melanoma, and esophageal cancers [#17, #18, #19, #20, #21, #23, #24]. A distinct isoform, LIMK2-1, lacks direct cofilin kinase output and instead, when phosphorylated by PKC, acts as a CPI-17-like inhibitor of PP1 and myosin phosphatase to indirectly maintain phospho-cofilin [#16, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that LIMK2 is a bona fide serine/threonine kinase, defining its catalytic identity and domain architecture.\",\n      \"evidence\": \"In vitro kinase assay on MBP from immunoprecipitated LIMK2 with two LIM motifs and a kinase domain\",\n      \"pmids\": [\"7651734\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No physiological substrate identified\", \"Regulation of catalytic activity unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved that LIMK2 isoforms differ in domain content and partition between nucleus and cytoplasm, raising the question of compartment-specific functions.\",\n      \"evidence\": \"Transfection, subcellular fractionation, immunofluorescence, and co-precipitation of isoforms LIMK2a/LIMK2b\",\n      \"pmids\": [\"8954941\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of 63/58-kDa partner proteins unknown\", \"Functional consequence of differential localization not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined PKC-delta phosphorylation of Ser-283 as a switch controlling LIMK2 nuclear import and cell cycle progression, linking post-translational control to function.\",\n      \"evidence\": \"FRAP live imaging, leptomycin B, site-directed mutagenesis, and in vitro kinase assay in endothelial cells\",\n      \"pmids\": [\"15923181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear substrate(s) of LIMK2 not identified\", \"Direct mechanism linking shuttling to cyclin D1 unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed LIMK2 in a Ras-Rho-ROCK pathway constrained by neurofibromin, showing its cofilin-phosphorylating activity drives stress fiber formation and motility.\",\n      \"evidence\": \"siRNA knockdown, phospho-cofilin Western blot, and NF1-GRD rescue epistasis\",\n      \"pmids\": [\"16169856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect NF1 effect not distinguished here\", \"Contribution relative to ROCK-cofilin baseline not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected LIMK2 to mitosis, showing spindle/midzone localization and activation upon mitotic arrest, distinct from LIMK1.\",\n      \"evidence\": \"Cell synchronization, in vitro kinase assay, and immunofluorescence\",\n      \"pmids\": [\"16455074\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trigger for mitotic hyperphosphorylation undefined here\", \"Mitotic substrate identity not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated ROCK1 preferentially activates LIMK2 in a migration-mode-specific manner, refining which migratory programs use this kinase.\",\n      \"evidence\": \"FRET live-cell imaging of direct interaction and substrate phosphorylation in polarized vs blebbing cells\",\n      \"pmids\": [\"18852895\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of ROCK1 preference for LIMK2 unknown\", \"In vivo relevance of mode specificity untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified LIMK2 as a p53 transcriptional target mediating survival after DNA damage, expanding its role beyond cytoskeletal control.\",\n      \"evidence\": \"siRNA, pharmacological LIMK inhibition, p53 target validation, and viability assays\",\n      \"pmids\": [\"21079653\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream survival effector of LIMK2 not defined\", \"Whether survival is cofilin-dependent unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed reciprocal Aurora A–LIMK2 phosphorylation and a positive-feedback loop required for Aurora-A-driven tumorigenesis, establishing LIMK2 as a mitotic oncogenic node.\",\n      \"evidence\": \"Analog-sensitive Aurora A chemical genetics, in vitro kinase assay, mutagenesis, and xenograft\",\n      \"pmids\": [\"22492986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which LIMK2 raises Aurora A levels unresolved\", \"Relative contribution of each phosphosite not dissected\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a cofilin-independent mitotic function: LIMK2 regulates astral microtubules and spindle orientation via TPPP downstream of RhoA-ROCK.\",\n      \"evidence\": \"RNAi epistasis and immunofluorescence of microtubules and spindle orientation\",\n      \"pmids\": [\"22328514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether LIMK2 directly phosphorylates TPPP not shown\", \"Coupling to actin-based mitotic roles unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed NF1 SecPH domain physically binds and inhibits LIMK2 by blocking ROCK activation, providing a direct molecular link between Ras and Rho/ROCK/LIMK2 signaling.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, and in vitro kinase inhibition assay\",\n      \"pmids\": [\"23082153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural interface of NF1-LIMK2 undefined\", \"Specificity over LIMK1 mechanism not explained\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Genetically proved the LIMK2-cofilin axis is required in vivo for keratinocyte F-actin nucleation and migration during eyelid development.\",\n      \"evidence\": \"LIMK2 knockout mouse with F-actin and phospho-cofilin immunofluorescence and eyes-open-at-birth phenotype\",\n      \"pmids\": [\"23071748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Redundancy with LIMK1 in other tissues not assessed\", \"Upstream activator in keratinocytes not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended LIMK2 microtubule regulation to drug sensitivity, linking it to microtubule acetylation and TPPP1 in neuroblastoma.\",\n      \"evidence\": \"siRNA, drug sensitivity and cell cycle assays, Western blot\",\n      \"pmids\": [\"23991158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular control of acetylation unclear\", \"Mechanism distinguishing actin vs microtubule roles undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated LIMK2 transduces Sema3A chemorepulsion in migrating cortical interneurons, defining a developmental neuronal guidance role.\",\n      \"evidence\": \"siRNA, chemotactic assays, brain slices, in utero electroporation\",\n      \"pmids\": [\"23519094\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor-to-LIMK2 signaling steps not mapped\", \"Substrate downstream of LIMK2 in interneurons unidentified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified a tumor-constraining role: Limk2 deletion enlarges colon tumors and increases GI stem cell proliferation, conserved with Drosophila.\",\n      \"evidence\": \"Limk2 knockout colitis-associated CRC model and immunostaining\",\n      \"pmids\": [\"23585469\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate mediating stem-cell restraint unknown\", \"Reconciliation with oncogenic roles context-dependence unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed LIMK2 downstream of BMPR2 via RhoA/ROCK and as a direct BMPR2 interactor driving osteosarcoma invasion and metastasis.\",\n      \"evidence\": \"iTRAQ phosphoproteomics, co-IP, and in vitro/in vivo invasion assays\",\n      \"pmids\": [\"28938584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct LIMK2 substrate in this context not defined\", \"BMPR2-LIMK2 binding interface unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the LIMK2-1 isoform as a non-canonical effector that inhibits PP1 toward cofilin rather than phosphorylating cofilin directly.\",\n      \"evidence\": \"In vitro kinase and PP1 activity assays, co-IP, and stress fiber imaging\",\n      \"pmids\": [\"30373762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase function of LIMK2-1, if any, not assigned a substrate\", \"Physiological context of isoform expression unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established the LIMK2-TWIST1 axis: direct phosphorylation stabilizes TWIST1 in a mutual stabilization loop driving EMT and tumor formation in CRPC.\",\n      \"evidence\": \"Chemical genetic substrate ID, in vitro kinase assay, mutagenesis, ubiquitylation assay, xenograft\",\n      \"pmids\": [\"30716360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosite-level mechanism of degradation protection partial\", \"Generality beyond CRPC not tested here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed LIMK2 is required in vivo for platelet cytoskeletal function, hemostasis, and thrombus formation.\",\n      \"evidence\": \"LIMK2a knockout mouse, platelet spreading, aggregation, and thrombus assays\",\n      \"pmids\": [\"31926945\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether effect is solely cofilin-mediated not shown\", \"Upstream platelet activator of LIMK2 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified PTEN as a direct LIMK2 substrate, linking hypoxia to PTEN degradation and PI3K/AKT activation in CRPC within a reciprocal degradation loop.\",\n      \"evidence\": \"In vitro kinase assay, mutagenesis, ubiquitylation, PTEN knockout mouse, xenograft\",\n      \"pmids\": [\"32931887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating PTEN degradation not identified\", \"Phosphosite stoichiometry in vivo unquantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established LIMK2 degrades SPOP by direct phosphorylation, stabilizing AR, ARv7, and c-Myc to drive tumorigenesis.\",\n      \"evidence\": \"In vitro kinase assay, phospho-resistant SPOP mutagenesis, ubiquitylation assay, xenograft\",\n      \"pmids\": [\"33311589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligase coupling SPOP phosphorylation to ubiquitylation undefined\", \"Crosstalk with other LIMK2 substrates not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified SRPK1 as a LIMK2 substrate whose inhibition phenocopies LIMK2 loss in blocking TNBC metastasis.\",\n      \"evidence\": \"SILAC phosphoproteomics, shRNA, pharmacological inhibition, in vivo metastasis model\",\n      \"pmids\": [\"32859889\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SRPK1 phosphosite(s) not mapped here\", \"Downstream splicing effectors not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Added NKX3.1 as a directly phosphorylated, degraded LIMK2 substrate in a reciprocal loop regulating AR and AKT signaling.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, ubiquitylation assay, xenograft\",\n      \"pmids\": [\"34066036\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mRNA downregulation unresolved\", \"Phosphosites not individually validated functionally\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated the LIMK2-cofilin axis is required in vivo for airway smooth muscle contractile force and actin polymerization in a stimulus-specific manner.\",\n      \"evidence\": \"LIMK2 knockout mouse, force measurements, F/G-actin ratio, phospho-cofilin blot\",\n      \"pmids\": [\"34353741\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Basis of 5-HT vs acetylcholine specificity unknown\", \"Upstream receptor-to-LIMK2 link not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed LIMK2 directs definitive endoderm versus neuroectoderm fate in hESCs through cofilin-dependent actin and EMT-gene control.\",\n      \"evidence\": \"siRNA, F-actin and p-cofilin assays, lineage marker RT-PCR\",\n      \"pmids\": [\"33977398\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional link to fate genes not defined\", \"Whether non-cofilin substrates contribute untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed LIMK2 in a Gα13-RhoA/C-ROCK pathway downstream of the TP receptor that restrains endothelial angiogenic sprouting.\",\n      \"evidence\": \"RNAi, pharmacological inhibition, spheroid sprouting, RhoA/C FRET biosensors\",\n      \"pmids\": [\"35525325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct LIMK2 substrate in endothelial sprouting not shown\", \"Relationship to focal-adhesion regulation mechanistic detail limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified the LIMK2→G3BP1→ESM1 pathway driving melanoma growth and metastasis via mRNA stabilization.\",\n      \"evidence\": \"Phosphoproteomics, shRNA, RNA-seq, rescue experiments, in vivo tumor models\",\n      \"pmids\": [\"36922679\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"G3BP1 phosphosite and consequence not detailed here\", \"How phosphorylation alters ESM1 mRNA stability unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a LIMK2-MST4-NPM1 cascade controlling centrosome clustering, explaining how LIMK2 supports mitotic fidelity in tumor cells.\",\n      \"evidence\": \"In vitro kinase assay, mutagenesis, co-IP, shRNA, xenograft and 4NQO mouse models\",\n      \"pmids\": [\"40775397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration with TPPP-based spindle role unresolved\", \"Whether MST4 activation occurs in non-cancer mitosis untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Characterized LIMK2-1 as a PKC-activated, CPI-17-like inhibitor of PP1c and myosin phosphatase with nanomolar potency, defining a phosphatase-regulatory mode for this isoform.\",\n      \"evidence\": \"Overexpression, co-IP with PP1c, in vitro phosphatase assay with IC50, phosphospecific antibody\",\n      \"pmids\": [\"40806479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signaling context regulating LIMK2-1 unknown\", \"Endogenous expression and abundance not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How LIMK2 selects between its canonical cofilin/cytoskeletal output and its diverse non-cytoskeletal substrate program (TWIST1, PTEN, SPOP, NKX3.1, SRPK1, G3BP1, MST4) in a given cell context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying determinant of substrate choice identified\", \"Structural basis of substrate recognition undefined\", \"Reconciliation of tumor-suppressive and oncogenic roles incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3, 8, 17, 18, 19, 24]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 11, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005819\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 15, 28]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 8, 9, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [17, 18, 19, 20, 23, 24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ROCK1\", \"PP1\", \"NF1\", \"BMPR2\", \"TWIST1\", \"MST4\", \"SPOP\", \"NKX3.1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}